Publications by authors named "A Angyal"
Whilst SARS-CoV-2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) recipients respond poorly. HSCT/CAR-T treatment ablates existing immune memory, with recipients requiring revaccination analogous to being vaccine naive. An optimal revaccination strategy for this cohort has not been defined.
View Article and Find Full Text PDFArticle Synopsis
- Spastic paraplegia 47 (SPG47) results from mutations in the AP4B1 gene, leading to symptoms like progressive spastic paraplegia, developmental delays, intellectual disability, and epilepsy.
- Researchers used a gene therapy approach with a viral vector (AAV9/hAP4B1) to deliver the correct AP4B1 gene into a mouse model, successfully correcting multiple disease symptoms and restoring protein levels.
- Preclinical safety studies in non-human primates showed no major side effects, setting the stage for potential clinical trials to treat SPG47 patients.
Background: Streptococcus pyogenes-related skin infections are increasingly implicated in the development of rheumatic heart disease (RHD) in lower-resourced settings, where they are often associated with scabies. The true prevalence of S. pyogenes-related pyoderma may be underestimated by bacterial culture.
View Article and Find Full Text PDFThis study, conducted in Debrecen, Hungary, aimed to analyse atmospheric particulate matter (APM or PM) through radiocarbon and PIXE analyses during the winter smog (23-25 January) and spring (15-18 May) seasons. The information presented in this pilot study aims to provide insight into the importance of utilising detailed characteristics of the mass size distributions of fossil carbon (f) and contemporary carbon (f) content. Additionally, it seeks to compare these characteristics with the size distributions of various elements to enable even more accurate PM source identification.
View Article and Find Full Text PDFArticle Synopsis
- The review discusses the purpose of biosimilars in reducing high costs associated with biologic treatments for inflammatory bowel disease (IBD) and highlights their current underutilization.
- Biosimilars, such as infliximab, adalimumab, and ustekinumab versions, have been shown to be similarly effective and safe as their branded counterparts, but their adoption is hindered by concerns over efficacy, safety, and market delays.
- To improve the uptake of biosimilars, collaboration among clinicians, patients, and healthcare systems is essential to enhance access and capitalize on cost-saving benefits.